Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 187,163 Shares of Stock

Posted by Brenda Bartman on Jun 24th, 2026

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CFO Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.97, for a total transaction of $3,176,156.11. Following the transaction, the chief financial officer directly owned 177,461 shares in the company, valued at approximately $3,011,513.17. The trade was a 51.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $12.86, for a total value of $227,840.62.
On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The shares were sold at an average price of $14.79, for a total value of $14,375.88.
On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total value of $230,498.17.
On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $27,000.00.

Relay Therapeutics Trading Up 3.4%

Shares of RLAY traded up $0.59 during trading hours on Wednesday, hitting $18.03. The company had a trading volume of 4,593,884 shares, compared to its average volume of 3,258,751. The company has a market capitalization of $3.45 billion, a PE ratio of -11.49 and a beta of 1.75. Relay Therapeutics, Inc. has a one year low of $3.03 and a one year high of $18.83. The company’s fifty day moving average price is $14.34 and its two-hundred day moving average price is $10.97.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.58 million. Analysts forecast that Relay Therapeutics, Inc. will post -1.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its stake in Relay Therapeutics by 591.7% in the 4th quarter. SG Americas Securities LLC now owns 220,949 shares of the company’s stock worth $1,869,000 after acquiring an additional 189,004 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in Relay Therapeutics during the 3rd quarter valued at about $399,000. Commodore Capital LP increased its holdings in shares of Relay Therapeutics by 27.3% in the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock valued at $88,740,000 after purchasing an additional 3,650,000 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of Relay Therapeutics in the fourth quarter valued at about $1,203,000. Finally, Mayport LLC acquired a new position in shares of Relay Therapeutics in the third quarter valued at about $259,000. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on RLAY. Wall Street Zen raised shares of Relay Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. HC Wainwright increased their price objective on Relay Therapeutics from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Citizens Jmp upped their target price on Relay Therapeutics from $19.00 to $21.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 20th. Barclays increased their price target on Relay Therapeutics from $21.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Relay Therapeutics has an average rating of “Buy” and an average target price of $23.30.

Get Our Latest Stock Analysis on Relay Therapeutics

Relay Therapeutics Company Profile

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.